Polyrizon Poised to Launch Pivotal Nasarix Trial for Seasonal Allergic Rhinitis

Groundbreaking Hydrogel Nasal Spray Enters First Human Study with Multi-Centre Trial Set to Commence

n

[City, State] – [Date] – Polyrizon, a company at the forefront of developing innovative solutions for respiratory ailments, has announced a significant milestone in its pursuit of a novel treatment for seasonal allergic rhinitis. The company has successfully completed agreements with five clinical sites, marking the final step in the contracting process for its upcoming Phase I/II clinical trial evaluating Nasarix Allergy Blocker (PL-14). This development signals the imminent commencement of the first human study for Nasarix, a pioneering hydrogel-based nasal spray designed to create a physical barrier within the nasal cavity, thereby preventing allergen contact.

n

The multi-centre, randomised, single-blind, two-arm study is designed to assess the efficacy and safety of Nasarix in patients suffering from the debilitating symptoms of seasonal allergic rhinitis. Up to 120 participants will be enrolled in the trial, which represents a crucial step in validating the therapeutic potential of this non-drug approach to allergy management.

n

The Nasarix Advantage: A Novel Hydrogel Barrier Approach

n

Seasonal allergic rhinitis, commonly known as hay fever, affects millions worldwide, causing symptoms such as sneezing, runny nose, itchy eyes, and nasal congestion. Current treatment options primarily include antihistamines, corticosteroids, and decongestants, which often come with side effects and may not provide complete symptom relief for all individuals. Polyrizon’s Nasarix offers a fundamentally different mechanism of action.

n

Nasarix is formulated as a hydrogel that, when sprayed into the nasal cavity, forms a thin, invisible, and temporary barrier. This physical shield is intended to trap airborne allergens, such as pollen and dust mites, before they can trigger the inflammatory cascade that leads to allergic reactions. By physically blocking allergen contact with the nasal mucosa, Nasarix aims to provide symptomatic relief without the systemic absorption associated with traditional drug therapies. This non-drug approach holds the promise of a favorable safety profile and reduced risk of side effects.

n

Trial Design: Rigorous Evaluation of Efficacy and Safety

n

The upcoming clinical trial is meticulously designed to provide robust data on Nasarix’s performance. It will be a multi-centre study, meaning it will be conducted at multiple research facilities, allowing for a diverse patient population and broader geographic representation. This approach enhances the generalizability of the study’s findings.

n

The trial is randomized, meaning that participants will be assigned to either the treatment group or the control group by chance, minimizing bias. The single-blind nature of the study ensures that neither the participants nor the researchers administering the treatment know which group a participant is assigned to until the study’s conclusion. This blinding is critical for preventing observer bias and ensuring objective assessment of outcomes.

n

The study will feature two arms:

n

n
• Treatment Arm: Participants in this group will receive Nasarix Allergy Blocker (PL-14).

n

• Control Arm: Participants in this group will receive an isotonic saline nasal spray. Isotonic saline is a neutral solution commonly used as a placebo in nasal spray studies, mimicking the physical act of spraying without introducing an active therapeutic agent.

n

n

Participants will be allocated equally to each arm, ensuring a balanced comparison between Nasarix and the placebo.

n

Key Efficacy and Safety Endpoints

n

The primary objective of the study is to evaluate the efficacy of Nasarix in reducing the symptoms of seasonal allergic rhinitis. The main efficacy measure will be the difference in mean daily reflective Total Nasal Symptom Score (rTNSS) between the treatment and control arms over the first 14 treatment days. The rTNSS is a validated patient-reported outcome measure that quantifies the severity of key nasal symptoms, including runny nose, stuffy nose, sneezing, and nasal itching. By tracking this score over time, researchers can determine if Nasarix provides a statistically significant improvement in symptom control compared to the placebo.

n

Safety is paramount in any clinical trial, and this study will rigorously monitor the safety profile of Nasarix. Safety will be tracked by:

n

n
• Monitoring the frequency and severity of treatment-emergent adverse events: This involves systematically collecting data on any new or worsening medical conditions that occur during the trial and assessing whether they are related to the study treatment.

n

• Evaluating local and overall tolerability: This will include assessing any discomfort, irritation, or other local reactions in the nasal passages, as well as general tolerability of the spray.

n

n

Beyond the primary efficacy endpoint, the study will also explore several secondary endpoints to provide a comprehensive understanding of Nasarix’s impact:

n

n
• Instantaneous Total Nasal Symptom Score (iTNSS): This measure captures symptom severity at a specific point in time, offering a real-time assessment of symptom relief.

n

• Impact on quality of life related to rhinoconjunctivitis: Allergic rhinitis can significantly impact a patient’s daily life, affecting sleep, work, and social activities. This endpoint will assess how Nasarix influences the overall quality of life for participants.

n

• Symptom-free days: This metric will quantify the number of days patients experience no or minimal allergy symptoms, indicating sustained symptom control.

n

• Use of relief medication: The study will track how often participants in each group need to use rescue medications to manage breakthrough symptoms, providing further insight into the effectiveness of Nasarix.

n

n

A Phased Approach to Study Execution

The completion of agreements with the five clinical sites signifies the end of the contracting phase and the initiation of the next critical stage: study preparation. Polyrizon is now actively progressing towards patient pre-screening and final recruitment preparations.

A key aspect of the trial’s scheduling will be its alignment with allergy seasons. Patient enrollment will be strategically timed to coincide with periods of peak allergen exposure in the local regions of the trial sites. This involves closely monitoring local pollen levels and weather conditions to ensure that participants are experiencing active allergen exposure, thus maximizing the opportunity to observe the effects of Nasarix. This proactive scheduling is vital for generating meaningful and relevant clinical data.

Official Response and Future Outlook

Tomer Izraeli, CEO of Polyrizon, expressed enthusiasm about reaching this pivotal stage. "Completing agreements with all five clinical sites is an important step in moving Nasarix from clinical preparation toward study execution," Izraeli stated. "We believe this study has the potential to generate important clinical evidence regarding the efficacy, safety, and tolerability of Nasarix and represents a significant milestone in our strategy to advance the product toward the US market."

The CEO highlighted the potential of Nasarix to address an unmet need in the allergy market. Polyrizon’s development of Nasarix as a non-drug option for blocking allergen contact underscores a growing trend towards seeking alternative and potentially safer therapeutic avenues. The company’s strategic focus on advancing the product towards the US market indicates a clear vision for commercialization and accessibility to patients.

The successful completion of this first human study would pave the way for further clinical development, potentially including larger Phase III trials and regulatory submissions. If Nasarix demonstrates favorable results, it could offer a valuable new option for the millions of individuals worldwide who struggle with the persistent and often disruptive symptoms of seasonal allergic rhinitis. The company’s commitment to rigorous scientific evaluation and patient well-being positions Nasarix as a promising contender in the evolving landscape of allergy treatment.